Latest News and Press Releases

More than half of patients with genetic diseases remain undiagnosed, even after performing Exome and Genome SequencingBy performing deep genetic analyses and Bio/Databank mining, CENTOGENE discovers...

Revenues more than doubled in FY 2020 compared to FY 2019 to a record €128.4 million, with Q4 2020 revenues nearly quadrupling year-over-year to a record €70.3 millionAchieved highest annual adjusted...

CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 14, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 08, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...

Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of the disease progression, diagnosis, and treatmentSignificant...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases...

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN and MUNICH, Germany, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that...

CAMBRIDGE, Mass. and ROSTOCK, Germany and HEIDELBERG, Germany and BERLIN, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that...